Stephanie Threatt PhD is a motivated, skilled and innovative research professional with exceptional communication and organizational skills. She attended Harvard College, where she graduated Cum Laude with a BA in Chemistry in 2014. She has aimed to further her knowledge related to chemistry and biochemistry by conducting research at various institutions, including UNC Charlotte, UCSF, Harvard University, and Massachusetts General Hospital (MGH). She completed her doctoral degree in Biochemistry and Molecular Biophysics in 2020 at the California Institute of Technology. Her PhD was completed with Professor Jacqueline Barton and focused on the development and execution of in vivo assessments of DNA-binding rhodium compounds that act as targeted chemotherapeutics. As a Howard Hughes Medical Institute Postdoctoral Scholar at Caltech, she employed computational chemistry techniques to study the chemical mechanism employed by the nitrogenase enzyme to convert atmospheric nitrogen into the bioavailable form of ammonia. Currently, Stephanie is a Formulation and Process Development research scientist at Gilead Sciences, where she works in a cross-functional capacity to advance the development of novel therapeutics through the use of biopharmaceutical, chemistry, and formulation science research techniques.